Most cited papers from Polyphor (Switzerland)

Polyphor (Switzerland)

What are the most cited papers from Polyphor (Switzerland)?

The most cited paper from Polyphor (Switzerland) is "Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa" (Nityakalyani Srinivas et al., 2010), with 557 citations. Next come "Chimeric peptidomimetic antibiotics against Gram-negative bacteria" (319) and "The Role of Neutrophil Elastase Inhibitors in Lung Diseases" (225).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 30 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Peptidomimetic Antibiotics Target Outer-Membrane Biogenesis in Pseudomonas aeruginosa Nityakalyani Srinivas et al. · Science Open access	18 Feb 2010	557
2	Chimeric peptidomimetic antibiotics against Gram-negative bacteria Anatol Luther et al. · Nature	23 Oct 2019	319
3	The Role of Neutrophil Elastase Inhibitors in Lung Diseases Eva Polverino, Edmundo Rosales-Mayor, Glenn E. Dale et al. · CHEST Journal	22 Apr 2017	225
4	Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction Rudi Fasan, Ricardo L. A. Dias, Kerstin Moehle et al. · Angewandte Chemie International Edition	6 Apr 2004	180
5	Transforming growth factor-β-dependent Wnt secretion controls myofibroblast formation and myocardial fibrosis progression in experimental autoimmune myocarditis Przemysław Błyszczuk, Björn Müller‐Edenborn, Tomáš Valenta et al. · European Heart Journal Open access	20 Apr 2016	172
6	Murepavadin: a new antibiotic class in the pipeline Ignacio Martín‐Loeches, Glenn E. Dale, Antoní Torres · Expert Review of Anti-infective Therapy	16 Feb 2018	144
7	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial Sònia Pernas et al. · The Lancet Oncology	26 Apr 2018	143
8	Use of a Pharmacophore Model To Discover a New Class of Influenza Endonuclease Inhibitors Kevin E. B. Parkes, Philipp Ermert, Jürg Fässler et al. · Journal of Medicinal Chemistry Open access	20 Feb 2003	143
9	The design, structures and therapeutic potential of protein epitope mimetics John A. Robinson, Steve DeMarco, Frank O. Gombert et al. · Drug Discovery Today	12 Sep 2008	141
10	C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-Regulatory Function Yong Wang, Klaus Dembowsky, Éric Chevalier et al. · Circulation Open access	30 Jan 2019	134
11	Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction Rudi Fasan, Ricardo L. A. Dias, Kerstin Moehle et al. · ChemBioChem Open access	Mar 2006	129
12	Inhibition of Lipopolysaccharide Transport to the Outer Membrane in Pseudomonas aeruginosa by Peptidomimetic Antibiotics Martina Werneburg, Katja Zerbe, Mario Juhas et al. · ChemBioChem Open access	17 Jul 2012	106
13	Protein Ligand Design: From Phage Display to Synthetic Protein Epitope Mimetics in Human Antibody Fc-Binding Peptidomimetics Ricardo L. A. Dias, Rudi Fasan, Kerstin Moehle et al. · Journal of the American Chemical Society	2 Feb 2006	96
14	Discovery of novel, highly potent and selective β-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles Steven J. DeMarco, Heiko Henze, Alexander Lederer et al. · Bioorganic & Medicinal Chemistry	29 Sep 2006	88
15	Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies Henri Merdjan, Manickam Rangaraju, Antoine Tarral · Clinical Drug Investigation	27 Mar 2015	82
16	Emerging peptide antibiotics with therapeutic potential Grégory Upert, Anatol Luther, Daniel Obrecht et al. · Medicine in Drug Discovery Open access	30 Dec 2020	81
17	Properties and structure–activity studies of cyclic β-hairpin peptidomimetics based on the cationic antimicrobial peptide protegrin I John A. Robinson, Sasalu C. Shankaramma, Peter Jetter et al. · Bioorganic & Medicinal Chemistry	5 Feb 2005	81
18	Lysophosphatidic Acid Receptors LPA1and LPA3Promote CXCL12-Mediated Smooth Muscle Progenitor Cell Recruitment in Neointima Formation Pallavi Subramanian, Ela Karshovska, Patricia Reinhard et al. · Circulation Research Open access	2 Apr 2010	70
19	Macrocyclic Hairpin Mimetics of the Cationic Antimicrobial Peptide Protegrin I: A New Family of Broad-Spectrum Antibiotics Sasalu C. Shankaramma, Zafiria Athanassiou, Oliver Zerbe et al. · ChemBioChem	28 Oct 2002	68
20	Chemokine Receptors as Targets for Cancer Therapy Xuesong Wu, Vivian C. Lee, Éric Chevalier et al. · Current Pharmaceutical Design	Mar 2009	68
21	Application of Dmb-Dipeptides in the Fmoc SPPS of Difficult and Aspartimide-Prone Sequences V.M.F. Cardona, I. Eberle, Sophie Barthélémy et al. · International Journal of Peptide Research and Therapeutics	6 Oct 2008	68
22	Investigation ofde novo Totally Random Biosequences, Part II Cristiano Chiarabelli, Jan Willem Vrijbloed, Davide De Lucrezia et al. · Chemistry & Biodiversity	Aug 2006	65
23	CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer Jingyu Xiang, Michelle A. Hurchla, Francesca Fontana et al. · Molecular Cancer Therapeutics Open access	12 Aug 2015	63
24	Protein epitope mimetic macrocycles as biopharmaceuticals Anatol Luther, Kerstin Moehle, Éric Chevalier et al. · Current Opinion in Chemical Biology Review	20 Apr 2017	60
25	Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China Helio Silva Sader, Glenn E. Dale, Paul R. Rhomberg et al. · Antimicrobial Agents and Chemotherapy Open access	24 Apr 2018	59
26	β-Hairpin protein epitope mimetic technology in drug discovery Daniel Obrecht, Éric Chevalier, Kerstin Moehle et al. · Drug Discovery Today Technologies Open access	17 Sep 2011	59
27	The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor Darja Karpova, Katrin Dauber, Gabriele Spohn et al. · Leukemia Open access	12 Sep 2013	56
28	At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer Gary D. Luker, Jinming Yang, Ann J. Richmond et al. · Journal of Leukocyte Biology Open access	26 Oct 2020	52
29	Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa Helio Silva Sader, Robert K. Flamm, Glenn E. Dale et al. · Journal of Antimicrobial Chemotherapy Open access	6 Jun 2018	52
30	Murepavadin antimicrobial activity against and resistance development in cystic fibrosis Pseudomonas aeruginosa isolates María Diez‐Aguilar, Marta Hernández-García, Marı́a-Isabel Morosini et al. · Journal of Antimicrobial Chemotherapy	2 Dec 2020	51
31	Innate Signaling Promotes Formation of Regulatory Nitric Oxide–Producing Dendritic Cells Limiting T-Cell Expansion in Experimental Autoimmune Myocarditis Gabriela Kania, Stefanie Siegert, Silvia Behnke et al. · Circulation Open access	14 May 2013	51
32	Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report Charles S. Dela Cruz et al. · Annals of the American Thoracic Society Open access	Jul 2021	50
33	37th International Symposium on Intensive Care and Emergency Medicine (part 3 of 3) And Sepsis Study Group et al. · Critical Care Open access1,024 authors	Mar 2017	50
34	Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial Darja Karpova, Susanne Bräuninger, Eliza Wiercinska et al. · Journal of Translational Medicine Open access	3 Jan 2017	50
35	Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis Philip Barth, Piet L.B. Bruijnzeel, Achim Wach et al. · Journal of Cystic Fibrosis Open access	6 Sep 2019	49
36	Advances in macrocyclic peptide-based antibiotics Anatol Luther, Christian Bisang, Daniel Obrecht · Bioorganic & Medicinal Chemistry	19 Aug 2017	49
37	Efficacy of the Novel Antibiotic POL7001 in Preclinical Models of Pseudomonas aeruginosa Pneumonia Cristina Cigana, Francesca Bernardini, Marcella Facchini et al. · Antimicrobial Agents and Chemotherapy Open access	14 Jun 2016	48
38	Design, Properties and Recent Application of Macrocycles in Medicinal Chemistry Philipp Ermert · CHIMIA International Journal for Chemistry Open access	25 Oct 2017	47
39	Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone Liang Weiping, Fuhao Wang, Qiuyan Chen et al. · Journal of Cancer Research and Clinical Oncology Open access	6 Jun 2019	46
40	Combinatorial Biomimetic Chemistry: Parallel Synthesis of a Small Library ofβ-Hairpin Mimetics Based on Loop III from Human Platelet-Derived Growth Factor B Lujong Jiang, Kerstin Moehle, Boopathy Dhanapal et al. · Helvetica Chimica Acta	20 Dec 2000	44
41	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma Amy K. Barone, Rajarshi Sengupta, Nicole M. Warrington et al. · Oncotarget Open access	9 Sep 2014	42
42	Susceptibility of Pseudomonas aeruginosa Recovered from Cystic Fibrosis Patients to Murepavadin and 13 Comparator Antibiotics Miquel Bart Ekkelenkamp, Rafael Cantón, María Diez‐Aguilar et al. · Antimicrobial Agents and Chemotherapy Open access	25 Nov 2019	41
43	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma Abdel Kareem Azab, İlyas Şahin, Feda Azab et al. · Blood Open access	30 Jul 2014	40
44	Recent Progress in the Discovery of Macrocyclic Compounds as Potential Anti-Infective Therapeutics Daniel Obrecht, John A. Robinson, Francesca Bernardini et al. · Current Medicinal Chemistry Open access	30 Dec 2008	40
45	Pharmacokinetics and Safety of Intravenous Murepavadin Infusion in Healthy Adult Subjects Administered Single and Multiple Ascending Doses Achim Wach, Klaus Dembowsky, Glenn E. Dale · Antimicrobial Agents and Chemotherapy Open access	2 Feb 2018	39
46	Investigation ofde novo Totally Random Biosequences, Part I Cristiano Chiarabelli, Jan Willem Vrijbloed, Richard M. Thomas et al. · Chemistry & Biodiversity	Aug 2006	39
47	Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti–Vascular Endothelial Growth Factor Therapy–Induced Glioma Dissemination Jean‐Pierre Gagner, Yasmeen Sarfraz, Valerio Ortenzi et al. · American Journal Of Pathology Open access	20 Jul 2017	38
48	A family of macrocyclic antibiotics with a mixed peptide–peptoid ß-hairpin backbone conformation Sasalu C. Shankaramma, Kerstin Moehle, S.P. James et al. · Chemical Communications	2003	38
49	A new general three component solution-phase synthesis of 2-amino-1,3-thiazole and 2,4-diamino-1,3-thiazole combinatorial libraries Thierry Masquelin, Daniel Obrecht · Tetrahedron	2001	37
50	POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL Edward Allan R. Sison, Daniel Magoon, Li Li et al. · Oncotarget Open access	3 Sep 2015	37

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.